Company profile
Stem Holdings, Inc.
OTC: STMH · Healthcare · Drug Manufacturers - Specialty & Generic
#578 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ 21GM —SS 29
v0.1 · 25/100 weight · pillars only
↑ 3-yr revenue growth, operating margin · ↓ market scale, filing timeliness
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$19.0M
Employees
75
as of 2026-07-12
Market cap
$667
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$16.6M$16.6M2022
Net income-$19.0M-$19.0M2023
Operating income-$3.7M-$3.7M2023
Total assets$13.3M$13.3M2023
Liabilities$14.0M$14.0M2023
Equity-$1.7M-$1.7M2023
Revenue trend
FY2017 – FY2022 · USD
FY17
FY19
FY20
FY20
FY21
FY22
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Stem Holdings, Inc.’s revenue?
Stem Holdings, Inc. booked $16.6M in FY2022 revenue, contracting 54% year over year — slower than 82% of Healthcare companies we track, at a -114.8% net margin.
Peers · Healthcare
Isodiol International Inc.——Inspire Veterinary Partners, Inc.——Seer, Inc.50DFOXO Technologies Inc.41DProfound Medical Corp.44DPatient Portal Technologies, Inc.——Neighbors
Palm Beach →Key facts
CEOMatthew J. Cohen
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersBoca Raton, FL
ExchangeOTC: STMH
Employees75
IPO date2021-01-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.